BioCentury | Jun 15, 1998
Company News

Genelabs Biotechnology, Genelabs, Long Bon Development Co. deal

...GNLB raised $4.3 million through the sale of an undisclosed number of shares of its Genelabs Biotechnology...
...NT$17.50 (US$0.51) per share. The sale reduces GNLB’s stake to 16 percent from 35 percent. Genelabs Biotechnology Ltd....
BioCentury | Mar 17, 1997
Company News

Genelabs, Bristol-Myers deal

...an initial three-year term, Genelabs Biotechnology will manufacture all of Bristol-Myers' Taiwan requirements for 15 products. Genelabs Biotechnology...
BioCentury | Jan 20, 1997
Clinical News

GL701 dehydroepiandrosterone (DHEA): Update

...compound will improve symptoms and clinical outcome. A joint investment with the government of Taiwan, Genelabs Biotechnology Ltd....
BioCentury | Jul 17, 1995
Company News

Genelabs deal

...GNLB and the finance ministry of Taiwan formed a joint venture to capitalize Genelabs Biotechnology Ltd. , GNLB's...
Items per page:
1 - 4 of 4
BioCentury | Jun 15, 1998
Company News

Genelabs Biotechnology, Genelabs, Long Bon Development Co. deal

...GNLB raised $4.3 million through the sale of an undisclosed number of shares of its Genelabs Biotechnology...
...NT$17.50 (US$0.51) per share. The sale reduces GNLB’s stake to 16 percent from 35 percent. Genelabs Biotechnology Ltd....
BioCentury | Mar 17, 1997
Company News

Genelabs, Bristol-Myers deal

...an initial three-year term, Genelabs Biotechnology will manufacture all of Bristol-Myers' Taiwan requirements for 15 products. Genelabs Biotechnology...
BioCentury | Jan 20, 1997
Clinical News

GL701 dehydroepiandrosterone (DHEA): Update

...compound will improve symptoms and clinical outcome. A joint investment with the government of Taiwan, Genelabs Biotechnology Ltd....
BioCentury | Jul 17, 1995
Company News

Genelabs deal

...GNLB and the finance ministry of Taiwan formed a joint venture to capitalize Genelabs Biotechnology Ltd. , GNLB's...
Items per page:
1 - 4 of 4